![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: Results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Tram T. Tran1, Darshan Mehta2,3, Andrea Goldstein3, Eric Cohen3, Yanjun Bao3, Yuri Sanchez Gonzalez31Cedars-Sinai Medical Center, Los Angeles, CA, United States; 2Schaeffer Center for Health Policy and Economics, University of Southern California, CA, United States; 3AbbVie Inc., North Chicago, IL, United States
EASL: Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. ANRS CO12 CirVir Cohort - (04/26/17)
EASL: THERAPY WITH DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH HCV-RELATED LYMPHOPROLIFERATIVE DISORDERS AND MIXED CRYOGLOBULINEMIA - (04/26/17)
![0428171](../images/042817/042817-2/0428171.gif)
![0428172](../images/042817/042817-2/0428172.gif)
![0428173](../images/042817/042817-2/0428173.gif)
![0428174](../images/042817/042817-2/0428174.gif)
![0428175](../images/042817/042817-2/0428175.gif)
![0428176](../images/042817/042817-2/0428176.gif)
![0428177](../images/042817/042817-2/0428177.gif)
![0428178](../images/042817/042817-2/0428178.gif)
![0428179](../images/042817/042817-2/0428179.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|